Project Grant R01MD021656
Award Date 9/1/26
Completion Date 3/31/31
Dollars Obligated $735K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
- The National Institute on Aging awarded the University of Florida $725,528 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct research on resistance exercise training for older adults with obesity using GLP-1 receptor agonists. The project will evaluate whether progressive, moderate to high-intensity resistance training mitigates muscle loss and strength decline in older adults initiating GLP-1 receptor agonist therapy for obesity treatment. The research addresses...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Adventhealth Orlando $151,816 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a real-world outcomes study of glucagon-like peptide-1 (GLP-1) medicines in type 1 diabetes patients. The project will assess weight loss, kidney disease progression, and major adverse events in type 1 diabetes patients treated with cardioprotective GLP-1 medicines...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Alabama at Birmingham $743,243 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a sequential multiple assignment randomized trial optimizing intensive behavioral therapy for obesity in adults aged 50 to 75 years. The trial will enroll 250 adults with obesity to determine the optimal first-line diet strategy—high-protein versus...
- The Department of Health and Human Services National Institutes of Health National Institute for Minority Health and Health Disparities awarded the University of South Florida $763,585 on July 28, 2026, under the Minority Health and Health Disparities Research program (CFDA 93.307) to conduct a randomized controlled trial evaluating ADAPT+, a multi-family lifestyle intervention designed to promote healthy eating and physical activity behaviors in youth aged 8–12 years with obesity and their...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Virginia $744,590 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a factorial experiment optimizing behavioral lifestyle intervention for adults prescribed next-generation anti-obesity medications. The project will recruit 608 adults with obesity or overweight with weight-related comorbidity who are prescribed second-generation...
- The National Institute on Aging awarded Mayo Clinic $443,850 on March 15, 2026, under the Aging Research program (CFDA 93.866) to study the real-world effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications on older adults. Mayo Clinic will use linked electronic health records from the Rochester Epidemiology Project to analyze age differences in GLP-1 RA response across a population-based cohort of 26,442 persons in the upper midwest. The study will test three primary...
- The National Heart, Lung, and Blood Institute awarded Trustees of Boston University (doing business as Boston University Medical Campus) $837,125 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on real-world effects of GLP-1 receptor agonists on cardiovascular-kidney-metabolic syndrome progression and lifetime costs in people with HIV and type 2 diabetes. The research addresses a critical gap in evidence-based guidance for type 2...
- The National Institute on Aging awarded Arizona State University $436,228 on June 1, 2026, under the Aging Research program (CFDA 93.866) to evaluate the impact of glucagon-like peptide-1 receptor agonists on sarcopenia in older adults. The research project will measure muscle mass and the mechanisms regulating muscle mass—including muscle protein synthesis and breakdown—using stable isotope tracer methodologies in older patients before and six months after GLP-1 RA treatment. The study will...
- The National Heart, Lung and Blood Institute awarded the University of North Carolina at Chapel Hill $1,505,062 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a factorial trial optimizing dietary adherence in a mobile behavioral weight loss intervention for adults. The award funds a six-month randomized trial enrolling 580 adults in a smartphone-based weight loss program that combines daily calorie goals with mobile dietary self-monitoring...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic Jacksonville $199,244 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year career development project investigating semaglutide's effects on preclinical cardiovascular disease markers in breast cancer survivors with obesity. The project will conduct a 24-week randomized controlled trial enrolling 50 breast cancer survivors with obesity, comparing lifestyle modification alone to...